相关实验视频
Updated: Jan 16, 2026

09:41
Performing and Processing FNA of Anterior Fat Pad for Amyloid
Published on: October 30, 2010
56.1K
什么心脏病专家应该知道关于氨基粉症
Rama Alashqar1, Ahmad Alkhatib2, Ala W Abdallah3
1Washington Hospital Center Program, MedStar Health, Georgetown University, Washington, DC 20010, USA.
Journal of clinical medicine
|September 27, 2025
概括
早期识别和准确诊断心肌粉症 (CA) 对于改善患者结果至关重要. 这篇评论强调了心脏病学家使用结构化,生物标志物和成像指导的方法来管理这种复杂的疾病.
科学领域:
- 心脏病学 心脏病学
- 心血管医学 心血管医学
- 氨基粉症研究研究
背景情况:
- 心脏 Amyloidosis (CA) 是一个被低诊断的心力衰竭的原因,心力衰竭与保存的喷射分数 (HFpEF).
- 由错误折叠的蛋白质 (ATTR或AL) 的细胞外沉积引起,导致心肌功能障碍.
- 通常呈现为限制性心肌病,可能涉及多个器官.
研究的目的:
- 提供心脏粉样性心脏病的心脏学重点审查.
- 强调早期识别,诊断策略和亚型差异化.
- 讨论ATTR和AL氨基粉症的不断发展和新兴疗法.
主要方法:
- 综述ATTR和AL CA的流行病学,病理生理学和临床表现.
- 评估关键的诊断工具:心声谱,心脏核磁共振,骨光学,蛋白质查,活检.
- 对临床表现的分析,心电图/成像"红旗",以及与像HCM这样的模仿者之间的差异化.
主要成果:
- 详细审查诊断工具和一个逐步的方法.
- 强调分期系统和心脏生物标志物的预后意义.
- 探索特定亚型疗法 (达拉图穆马布,塔法米迪斯,基因沉默剂) 和新型治疗方法 (CRISPR).
结论:
- 及时识别和准确诊断CA对于改善结果至关重要.
- 心脏病专家必须在快速发展的诊断和治疗中领导多学科的护理.
- 一种结构化,生物标志物和成像指导的方法可以改善诊断,预后和患者管理.
更多相关视频
相关概念视频
Cardiomyopathy V: Interprofessional Care
338
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
338
Cardiomyopathy IV: Restrictive Cardiomyopathy
455
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
455
Cardiomyopathy I: Introduction and Classification
504
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
504
Cardiomyopathy III: Hypertrophic Cardiomyopathy
411
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
411
Amyloid Fibrils
6.3K
6.3K
Amyloid Fibrils
11.6K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
11.6K

